All In Biotech

Drug Trial Radar · NCT01609062

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Last checked: Nov 20, 2026Latest source record: Feb 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

25

Actual

Start

Apr 2012

Primary completion

Nov 2014

Study completion Nov 2014

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
May 31, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks. Secondary objectives were to investigate the effect of the two doses on exercise capacity for up to 196 weeks. In addition, the pharmacokinetic (PK) parameters of both doses of BMN 110 was assessed.

Conditions

  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome
  • MPS IVA

Interventions

  • BMN 110Drug

    Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.

  • BMN 110Drug

    Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EvaluationTime frame: Entire Study Period, up to 192 weeks or ETV (early termination visit)

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Oakland, California

  • Site not named

    Chicago, Illinois

  • Site not named

    New York, New York

  • Site not named

    Houston, Texas

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Sherbrook, Quebec, Canada

  • Site not named

    Hamburg, Germany

  • Site not named

    Manchester, United Kingdom

  • Site not named

    Belfast, Northern Ireland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.